ROS1 and non-small cell lung carcinoma: ,8,9 In an integrated analysis of 3 phase I/II trials (ALKA-372-001: EudraCT 2012–000148–88; STARTRK-1: NCT02097810; STARTRK-2: NCT02568267), entrectinib yielded an objective response rate (ORR) of 68%, median duration of response (DoR) of 20.5 months and median progression-free survival (PFS) of 15.7 months, and was well tolerated in patients with locally advanced/metastatic ROS1 fusion-positive NSCLC (N = 168).9